Evidence map›Paper›PMID 41057453›Full record

ArticleScientific reports2025

The study of dual-phase

Libo Zhang, Xing Wan, Kai Ji, Kun Chen, Xiang Zhu, Qian Su, Shudan Zhai, Wengui Xu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Clinical study ofPeerJ · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Libo Zhang *Department of Molecular Imaging and Nuclear Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Huanhu West Road, Hexi District, Tianjin, 300060, China.
Xing Wan *Department of Molecular Imaging and Nuclear Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Huanhu West Road, Hexi District, Tianjin, 300060, China.
Kai Ji *Department of Pain Relief, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Tianjin, 300060, China.
Kun ChenHangzhou Institute of Medicine (HIM), Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Xiang ZhuDepartment of Molecular Imaging and Nuclear Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Huanhu West Road, Hexi District, Tianjin, 300060, China.
Qian SuDepartment of Molecular Imaging and Nuclear Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Huanhu West Road, Hexi District, Tianjin, 300060, China.
Shudan ZhaiDepartment of Molecular Imaging and Nuclear Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Huanhu West Road, Hexi District, Tianjin, 300060, China.
Wengui XuDepartment of Molecular Imaging and Nuclear Medicine, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for China, Huanhu West Road, Hexi District, Tianjin, 300060, China. wenguixy@yeah.net.

Funding

Tianjin Key Medical Discipline (Specialty) Construction Project TJYXZDXK-009A
6 · The paper itself

Abstract

The morphology of benign and malignant solitary pulmonary lesions sometimes overlaps, making the differentiation difficult. This research aimed to create a radiomics-based prediction model using dual-phase

Indexed as

Fluorodeoxyglucose F18Lung NeoplasmsPositron Emission Tomography Computed TomographySolitary Pulmonary NoduleAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRadiopharmaceuticalsROC CurveFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG PET/CTDual-phaseRadiomicsSolitary pulmonary lesion

Identifiers

PMID41057453
PMCPMC12504460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.